Literature DB >> 11279659

Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.

L T Busby1, A Weyman, G M Rodgers.   

Abstract

Low-molecular-weight heparins, such as enoxaparin, are increasingly being used for treatment of venous thromboembolism. We describe two patients who received therapeutic enoxaparin for several months. Although their serum creatinine values were normal, both had mild renal insufficiency (creatinine clearance 60-70 ml/min), and both accumulated the drug abnormally and experienced clinical bleeding. These results suggest that patients receiving enoxaparin (or other low-molecular-weight heparins) in therapeutic doses for periods of more than 4 weeks should be considered for laboratory monitoring to avoid bleeding. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11279659     DOI: 10.1002/ajh.1077

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  Uremic pericarditis with tamponade following prolonged continuous hemofiltration.

Authors:  E Zakynthinos; T Vassilakopoulos; P Politis; Z Daniil; C Roussos; S G Zakynthinos
Journal:  Intensive Care Med       Date:  2001-10-25       Impact factor: 17.440

2.  Medication errors in patients with severe chronic kidney disease and acute coronary syndrome: the impact of computer-assisted decision support.

Authors:  Richard V Milani; Sylvia A Oleck; Carl J Lavie
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

3.  Chronic kidney disease is an independent predictor of pocket hematoma after pacemaker and defibrillator implantation.

Authors:  Imdad Ahmed; Elie Gertner; William B Nelson; Chad M House; Dennis W X Zhu
Journal:  J Interv Card Electrophysiol       Date:  2010-10-13       Impact factor: 1.900

Review 4.  Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer.

Authors:  Lisa Baumann Kreuziger; Michael Streiff
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads.

Authors:  F Scotté; J B Rey; V Launay-Vacher
Journal:  Support Care Cancer       Date:  2012-09-09       Impact factor: 3.603

Review 6.  Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.

Authors:  Jawed Fareed; Debra Hoppensteadt; Jeanine Walenga; Omer Iqbal; Qing Ma; Walter Jeske; Taqdees Sheikh
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Clinical Scenarios for Discordant Anti-Xa.

Authors:  Jesus Vera-Aguilera; Hindi Yousef; Diego Beltran-Melgarejo; Teng Hugh Teng; Ramos Jan; Mary Mok; Carlos Vera-Aguilera; Eduardo Moreno-Aguilera
Journal:  Adv Hematol       Date:  2016-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.